Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML and determine the best dosage.

Inclusion Criteria:

• Patients with CD123+ Refractory or Relapsed AML
• To be aged 3 to 80 years
• Expression of CD123 in Blast ≥90%
• ECOG score ≤2
• Voluntary participation in the clinical trials and sign the informed consent.

Exclusion Criteria:

• Intracranial hypertension or unconsciousness
• Respiratory failure
• CD19 negative
• Disseminated intravascular coagulation
• ALT /AST>3 x normal value; Creatinine> 1.5 x normal value; Bilirubin >2.0 x -normal value
• Hematosepsis or Uncontrolled active infection
• Uncontrolled diabetes
• Abalienation;
• Patients in pregnancy or breast-feeding period
• Previously treatment with any gene therapy products
• Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial